Status:
UNKNOWN
Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy
Lead Sponsor:
Hallym University Medical Center
Collaborating Sponsors:
Hallym University
Conditions:
Macular Edema
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate in a prospective study the efficacy of intravitreal autologous plasmin enzyme in macular edema and to analyze the fibrinolytic system in vitreous body.
Detailed Description
Autologous plasmin enzyme has been used to liquefy the gel structure of the vitreous body and to decrease the adherence of the posterior vitreous cortex to the inner limiting membrane in clinical stud...
Eligibility Criteria
Inclusion
- eyes with macular edema
- those who showed poor outcomes in visual acuity or macular thickness after grid laser,triamcinolone,or bevacizumab therapy or a combination of these treatments.
Exclusion
- uncontrolled blood pressure (systolic and diastolic blood pressure greater than 150 and 90 mm Hg, respectively)
- renal insufficiency
- intraocular surgery or any intravitreal treatment during the previous 3 months
- history of ocular hypertension and/or glaucoma
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01478516
Start Date
November 1 2011
End Date
November 1 2013
Last Update
December 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ji Won Lim
Chuncheon, Gangwon-do, South Korea, 200-704